Hanson & Doremus Investment Management Has $842,000 Stock Holdings in Bristol Myers Squibb Company $BMY

Hanson & Doremus Investment Management cut its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 3.8% in the second quarter, HoldingsChannel reports. The firm owned 18,188 shares of the biopharmaceutical company’s stock after selling 709 shares during the period. Hanson & Doremus Investment Management’s holdings in Bristol Myers Squibb were worth $842,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. V Square Quantitative Management LLC raised its position in shares of Bristol Myers Squibb by 5.2% during the second quarter. V Square Quantitative Management LLC now owns 48,828 shares of the biopharmaceutical company’s stock valued at $2,260,000 after buying an additional 2,429 shares during the last quarter. Patton Albertson Miller Group LLC increased its holdings in shares of Bristol Myers Squibb by 17.3% during the second quarter. Patton Albertson Miller Group LLC now owns 5,574 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 824 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Bristol Myers Squibb by 0.3% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 2,599,492 shares of the biopharmaceutical company’s stock valued at $120,330,000 after purchasing an additional 7,095 shares during the last quarter. Guyasuta Investment Advisors Inc. boosted its stake in Bristol Myers Squibb by 0.9% in the second quarter. Guyasuta Investment Advisors Inc. now owns 48,052 shares of the biopharmaceutical company’s stock valued at $2,224,000 after acquiring an additional 409 shares during the last quarter. Finally, Financial Partners Group LLC boosted its position in shares of Bristol Myers Squibb by 16.0% during the second quarter. Financial Partners Group LLC now owns 7,704 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 1,065 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research report on Tuesday, August 5th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Finally, Citigroup decreased their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average price target of $56.38.

Bristol Myers Squibb Stock Up 1.6%

Shares of Bristol Myers Squibb stock opened at $44.12 on Monday. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The company’s fifty day simple moving average is $46.63 and its two-hundred day simple moving average is $49.00. The company has a market cap of $89.80 billion, a P/E ratio of 17.79, a PEG ratio of 2.26 and a beta of 0.35. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the prior year, the firm posted $2.07 EPS. Bristol Myers Squibb’s revenue for the quarter was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.6%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.